The Market Reports

Synopsis

The global market for Cell Banking Outsourcing was estimated to be worth US$ 9372 million in 2024 and is forecast to a readjusted size of US$ 26485 million by 2031 with a CAGR of 16.1% during the forecast period 2025-2031.

Cell Banking Outsourcing refers to the practice of delegating the critical processes of collecting, processing, expanding, and storing cell samples—such as stem cells, immune cells, or genetically engineered cells—to specialized third-party service providers. This service involves standardized GMP-compliant biobanking procedures, stringent quality control, and full lifecycle data traceability. With the rapid expansion of precision medicine, cell therapies, and biopharmaceutical R&D, outsourced cell banking is becoming a vital infrastructure across the global healthcare and life sciences industries, bridging the gap from clinical research to commercial application.

The global biopharmaceutical sector is undergoing structural transformation, with emerging therapies such as cell and gene therapy driving a surge in demand for large-scale, high-quality cell sample banking. Biotech companies are increasingly favoring asset-light R&D models, outsourcing cell banking, QC, and storage to specialized providers with GMP or ISO certifications to enhance efficiency and reduce operational burden. Meanwhile, national policies in countries like China, the U.S., South Korea, and Singapore continue to prioritize cell banking as a strategic infrastructure initiative. These factors jointly propel the Cell Banking Outsourcing market into a high-growth trajectory, attracting both capital and industry attention as a critical enabling service. Despite strong demand, the sector faces considerable hurdles. Global disparities in regulation—especially in areas such as sample cross-border transfer, ethical approvals, and data sovereignty—present compliance complexities. The industry has high entry barriers, requiring significant investment in infrastructure, certified personnel, and quality systems. Client expectations around data integrity, biosafety, and long-term storage reliability are also rising, leading to market consolidation. As a result, while leading providers strengthen their positions, smaller players face increasing operational and competitive pressures.Demand is shifting from early-stage academic and research applications to late-phase and commercial clinical programs, especially in CAR-T, iPSC-based regenerative therapies, and personalized immunotherapies.

Phase III+ trials require stricter sample handling and storage protocols. Additionally, global pharma and CRO/CMO players are reshaping their supply chains, driving the adoption of multi-site collection, regionalized biobanking, and real-time digital traceability systems. The future will favor providers offering integrated, automated, and fully compliant services—emerging as platform-centric and ecosystem-leading companies in a rapidly maturing landscape.

This report aims to provide a comprehensive presentation of the global market for Cell Banking Outsourcing, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Cell Banking Outsourcing by region & country, by Type, and by Application.

The Cell Banking Outsourcing market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cell Banking Outsourcing.

Market Segmentation

By Company

• SGS Life Sciences
• Lonza
• CCBC
• Vcanbio
• AMAG Pharmaceuticals
• ViaCord
• Thermo Fisher
• Wuxi Apptec
• CordLife
• Esperite
• Reliance Life Sciences
• Lifecell
• Cryo-Cell
• Toxikon
• Goodwin Biotechnology
• Texcell
• Cryo Stemcell

Segment by Type

• Stem Cell Banking
• Non-stem Cell Banking

Segment by Application

• Cell Bank Storage
• Bank Characterization and Testing
• Cell Bank Preparation

Segment by Region

• North America: United States, Canada, and Mexico
• Europe: United Kingdom, Germany, France, Spain, Italy, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, and Rest of Asia Pacific
• Middle East & Africa: Saudi Arabia, South Africa, and Rest of MEA
• Latin America: Brazil, Argentina, and Rest of Latin America

*If you need a regional or country-specific version, or customized segmentation, we can tailor the report to your requirements.